Drug intelligence / Profile preview

calcipotriene + betamethasone dipropionate + apremilast

Development stage: Unknown
Lead developer: LEO Pharma
Modality: Small Molecules
Administration: Topical, Oral

Overview

A combination therapy consisting of topical calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam and oral apremilast for the treatment of moderate to severe plaque psoriasis. Calcipotriene is a vitamin D analog, betamethasone dipropionate is a corticosteroid, and apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor. This combination approach has shown improved efficacy compared to monotherapy with either component, with most partial responders to apremilast achieving PASI 75 after adding Cal/BD foam.

Targets

GR (Glucocorticoid receptor)PDE4 (Phosphodiesterase 4A1)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on calcipotriene + betamethasone dipropionate + apremilast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on calcipotriene + betamethasone dipropionate + apremilast.

Explore the full profile